{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:04:52Z","timestamp":1767168292205,"version":"build-2238731810"},"reference-count":43,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,9,21]]},"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the cost-effectiveness of salvage cryotherapy (SC) in men with radiation recurrent prostate cancer (RRPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cost-utility analysis using decision analytic modelling by a Markov model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting and methods<\/jats:title>\n                    <jats:p>Compared SC and androgen deprivation therapy (ADT) in a cohort of patients with RRPC (biopsy proven local recurrence, no evidence of metastatic disease). A literature review captured published data to inform the decision model, and resource use data were from the Scottish Prostate Cryotherapy Service. The model was run in monthly cycles for RRPC men, mean age of 70\u2005years. The model was run over the patient lifetime, to assess changes in patient health states and the associated quality of life, survival and cost impacts. Results are reported in terms of the discounted incremental costs and discounted incremental quality-adjusted life years (QALYs) gained between the 2 alternative interventions. Probabilistic sensitivity analysis used a 10\u2005000 iteration Monte Carlo simulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SC has a high upfront treatment cost, but delays the ongoing monthly cost of ADT. SC is the dominant strategy over the patient lifetime; it is more effective with an incremental 0.56 QALY gain (95% CI 0.28 to 0.87), and less costly with a reduced lifetime cost of \u00a329\u2005719 (\u20ac37\u2005619) (95% CI \u221251\u2005985 to \u22129243). For a ceiling ratio of \u00a330\u2005000, SC has a 100% probability to be cost-effective. The cost neutral point was at 3.5\u2005years, when the upfront cost of SC (plus any subsequent cumulative cost of side effects and ADT) equates the cumulative cost in the ADT arm. Limitations of our model may arise from its insensitivity to parameter or structural uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The platform for SC versus ADT cost-effective analysis can be employed to evaluate other treatment modalities or strategies in RRPC. SC is the dominant strategy, costing less over a patient's lifetime with improvements in QALYs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>This economic analysis was undertaken as part of the CROP RCT study ISRCTN:72677390; it was a pre-trial economic model developed and analysed during the pre-results stage of the RCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-007925","type":"journal-article","created":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T08:27:23Z","timestamp":1445329643000},"page":"e007925","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer"],"prefix":"10.1136","volume":"5","author":[{"given":"Kathleen A","family":"Boyd","sequence":"first","affiliation":[{"name":"Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob J","family":"Jones","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK"},{"name":"Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Bearsden, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Paul","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Birrell","sequence":"additional","affiliation":[{"name":"Department of Urology, NHS Greater Glasgow and Clyde, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H","family":"Briggs","sequence":"additional","affiliation":[{"name":"Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hing Y","family":"Leung","sequence":"additional","affiliation":[{"name":"Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Bearsden, Glasgow, UK"},{"name":"Department of Urology, NHS Greater Glasgow and Clyde, Glasgow, UK"},{"name":"Beatson Institute for Cancer Research, Bearsden, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,10,19]]},"reference":[{"key":"2025120619100290000_5.10.e007925.1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.eururo.2011.01.007","article-title":"Radiorecurrent prostate cancer: an emerging and largely mismanaged epidemic","volume":"60","author":"Jones","year":"2011","journal-title":"Eur Urol"},{"key":"2025120619100290000_5.10.e007925.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0133"},{"key":"2025120619100290000_5.10.e007925.3","unstructured":"Cancer Research UK. Cancer Statistics Key Stats: Prostate Cancer, November 2012. http:\/\/publications.cancerresearchuk.org\/downloads\/Product\/CS_KF_PROSTATE.pdf (accessed 3 Jun 2013)."},{"key":"2025120619100290000_5.10.e007925.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10365.x"},{"key":"2025120619100290000_5.10.e007925.5","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0022-5347(05)64673-3","article-title":"Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor","volume":"168","author":"Grossfeld","year":"2002","journal-title":"J Urol"},{"key":"2025120619100290000_5.10.e007925.6","unstructured":"Liufu Z , Newton S , Hiller JE . Cryotherapy for recurrent prostate cancer and renal cancer. MSAC 1124. Australia: Medical Services Advisory Committee, 2009."},{"issue":"11A","key":"2025120619100290000_5.10.e007925.7","first-page":"111","article-title":"NCCN practice guidelines for prostate cancer","volume":"14","author":"Bahnson","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"2025120619100290000_5.10.e007925.8","unstructured":"National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment. Full Guideline. UK: National Collaborating Centre for Cancer, 2008."},{"key":"2025120619100290000_5.10.e007925.9","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000155534.54711.60"},{"key":"2025120619100290000_5.10.e007925.10","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000140960.63108.39"},{"key":"2025120619100290000_5.10.e007925.11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3816\/CGC.2003.n.018","article-title":"Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up","volume":"2","author":"Bahn","year":"2003","journal-title":"Clin Prostate Cancer"},{"key":"2025120619100290000_5.10.e007925.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07045.x"},{"key":"2025120619100290000_5.10.e007925.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.12.012"},{"key":"2025120619100290000_5.10.e007925.14","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00345-012-0982-2","article-title":"Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry","volume":"31","author":"Spiess","year":"2012","journal-title":"World J Urol"},{"key":"2025120619100290000_5.10.e007925.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.07.008"},{"key":"2025120619100290000_5.10.e007925.16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/bjc.2014.316","article-title":"Feasibility study of a randomised controlled trial to compare (deferred) androgen deprivation therapy and cryotherapy in men with localised radiation-recurrent prostate cancer","volume":"111","author":"Salji","year":"2014","journal-title":"Br J Cancer"},{"key":"2025120619100290000_5.10.e007925.17","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal: 2013. National Institute for Health and Clinical Excellence, 2013."},{"key":"2025120619100290000_5.10.e007925.18","unstructured":"National Services Division. Scottish prostate cryotherapy service. Scottish Government; NHS National Services Scotland, 2012."},{"key":"2025120619100290000_5.10.e007925.19","unstructured":"British National Formulary. BNF 67, March - September 2014. www.bnf.org\/bnf (accessed 15 Jul 2014)."},{"key":"2025120619100290000_5.10.e007925.20","unstructured":"Information Services Division. Scottish health service costs book 2014. Information Services Division, 2015."},{"key":"2025120619100290000_5.10.e007925.21","unstructured":"Department of Health. NHS reference costs: financial year 2013\u20132014. online, Department of Health, 2015."},{"key":"2025120619100290000_5.10.e007925.22","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X0202200408"},{"key":"2025120619100290000_5.10.e007925.23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069243"},{"key":"2025120619100290000_5.10.e007925.24","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1464-410X.2007.06802.x","article-title":"Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials","volume":"99","author":"Boustead","year":"2007","journal-title":"BJU Int"},{"key":"2025120619100290000_5.10.e007925.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.529"},{"key":"2025120619100290000_5.10.e007925.26","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200017050-00006"},{"key":"2025120619100290000_5.10.e007925.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d1766"},{"key":"2025120619100290000_5.10.e007925.28","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12472398"},{"issue":"Suppl 2","key":"2025120619100290000_5.10.e007925.29","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1524-4733.2009.00550.x","article-title":"Health technology assessment: lessons learned from around the world\u2014an overview","volume":"12","author":"O'Donnell","year":"2009","journal-title":"Value Health"},{"key":"2025120619100290000_5.10.e007925.30","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1200\/JCO.2000.18.18.3302","article-title":"Systematic overview of cost-utility assessments in oncology","volume":"18","author":"Earle","year":"2000","journal-title":"J Clin Oncol"},{"key":"2025120619100290000_5.10.e007925.31","doi-asserted-by":"crossref","unstructured":"Cleemput I , Neyt M , Thiry N , et al . Threshold values for cost-effectiveness in health care Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre (KCE), 2008. KCE reports 100C","DOI":"10.57598\/R100C"},{"key":"2025120619100290000_5.10.e007925.32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.086"},{"key":"2025120619100290000_5.10.e007925.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.04547.x"},{"key":"2025120619100290000_5.10.e007925.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.04.005"},{"key":"2025120619100290000_5.10.e007925.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.04.006"},{"key":"2025120619100290000_5.10.e007925.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00390-8"},{"key":"2025120619100290000_5.10.e007925.37","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.21.1731"},{"key":"2025120619100290000_5.10.e007925.38","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24523"},{"key":"2025120619100290000_5.10.e007925.39","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200525020-00002"},{"key":"2025120619100290000_5.10.e007925.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.06.012"},{"key":"2025120619100290000_5.10.e007925.41","unstructured":"Office for National Statistics. Interim Lifetables United Kingdom 2008\u20132010. Office for National Statistics, 2011."},{"key":"2025120619100290000_5.10.e007925.42","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X11401031"},{"key":"2025120619100290000_5.10.e007925.43","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200006000-00004"}],"updated-by":[{"DOI":"10.1136\/bmjopen-2015-007925corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T00:00:00Z","timestamp":1470182400000}}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-007925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T03:10:16Z","timestamp":1765077016000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-007925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10,19]]},"published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1136\/bmjopen-2015-007925"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-007925","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}